• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Premature Fecal Immunochemical Testing in British Columbia Canada: a Retrospective Review of Physician and Screening Participant Characteristics.加拿大不列颠哥伦比亚省提前粪便免疫化学检测:对医生和筛查参与者特征的回顾性分析。
J Gen Intern Med. 2020 Feb;35(2):444-448. doi: 10.1007/s11606-019-05399-4. Epub 2019 Dec 12.
2
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.多次粪便免疫化学检测受试者的间期结直肠癌发病率。
Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5.
3
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.粪便免疫化学试验筛查与结直肠癌死亡风险。
JAMA Netw Open. 2024 Jul 1;7(7):e2423671. doi: 10.1001/jamanetworkopen.2024.23671.
4
Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests.在粪便免疫化学检测结果为阴性的无症状、平均风险受试者中,结肠镜检查的癌症检出率较低。
Clin Gastroenterol Hepatol. 2020 Dec;18(13):2929-2936.e1. doi: 10.1016/j.cgh.2020.01.029. Epub 2020 Jan 31.
5
Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.参与者相关的粪便免疫化学检测在结直肠癌筛查中的假阳性和假阴性的危险因素:系统评价和荟萃分析。
Am J Gastroenterol. 2018 Dec;113(12):1778-1787. doi: 10.1038/s41395-018-0212-7. Epub 2018 Aug 29.
6
Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.第一轮粪便免疫化学筛选试验阴性结果后间隔期结直肠癌的发生率,按截止值和参与者的性别及年龄划分。
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1493-1500. doi: 10.1016/j.cgh.2019.08.021. Epub 2019 Aug 20.
7
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
8
Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.粪便免疫化学试验与结肠镜检查用于息肉切除术后监测的比较:一项准确性、可接受性和经济学研究。
Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010.
9
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.结肠镜检查外展与粪便免疫化学检测外展对结直肠癌筛查完成率的影响:一项随机临床试验。
JAMA. 2017 Sep 5;318(9):806-815. doi: 10.1001/jama.2017.11389.
10
"Finding the Right FIT": Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics.“找到合适的匹配度”:农村患者对粪便免疫化学检测(FIT)特征的偏好
J Am Board Fam Med. 2017 Sep-Oct;30(5):632-644. doi: 10.3122/jabfm.2017.05.170151.

本文引用的文献

1
Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial.数字健康干预对脆弱患者接受结直肠癌筛查的影响:一项随机对照试验。
Ann Intern Med. 2018 Apr 17;168(8):550-557. doi: 10.7326/M17-2315. Epub 2018 Mar 13.
2
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.结肠镜检查外展与粪便免疫化学检测外展对结直肠癌筛查完成率的影响:一项随机临床试验。
JAMA. 2017 Sep 5;318(9):806-815. doi: 10.1001/jama.2017.11389.
3
Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial.医生告知患者未坚持进行结直肠癌筛查对患者参与粪便免疫化学检测癌症筛查的影响:一项随机临床试验。
JAMA. 2017 Sep 5;318(9):816-824. doi: 10.1001/jama.2017.11387.
4
Using Outreach to Improve Colorectal Cancer Screening.通过拓展服务来改善结直肠癌筛查
JAMA. 2017 Sep 5;318(9):799-800. doi: 10.1001/jama.2017.10606.
5
Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.结直肠癌筛查:美国多学会专家组关于结直肠癌筛查的医师和患者建议。
Gastroenterology. 2017 Jul;153(1):307-323. doi: 10.1053/j.gastro.2017.05.013. Epub 2017 Jun 9.
6
Colorectal cancer statistics, 2017.结直肠癌统计数据,2017 年。
CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1.
7
Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.结直肠癌筛查的依从性:四轮基于粪便免疫化学检测的筛查
Br J Cancer. 2017 Jan 3;116(1):44-49. doi: 10.1038/bjc.2016.399. Epub 2016 Dec 6.
8
Recommendations on screening for colorectal cancer in primary care.基层医疗中结直肠癌筛查的建议。
CMAJ. 2016 Mar 15;188(5):340-348. doi: 10.1503/cmaj.151125. Epub 2016 Feb 22.
9
Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration.退伍军人健康管理局中潜在不适当的结直肠癌筛查率及其相关因素。
J Gen Intern Med. 2015 Jun;30(6):732-41. doi: 10.1007/s11606-014-3163-8. Epub 2015 Jan 21.
10
Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.粪便免疫化学检测用于结直肠癌的准确性:系统评价和荟萃分析。
Ann Intern Med. 2014 Feb 4;160(3):171. doi: 10.7326/M13-1484.

加拿大不列颠哥伦比亚省提前粪便免疫化学检测:对医生和筛查参与者特征的回顾性分析。

Premature Fecal Immunochemical Testing in British Columbia Canada: a Retrospective Review of Physician and Screening Participant Characteristics.

机构信息

University of British Columbia, Vancouver, Canada.

BC Cancer Agency, Vancouver, Canada.

出版信息

J Gen Intern Med. 2020 Feb;35(2):444-448. doi: 10.1007/s11606-019-05399-4. Epub 2019 Dec 12.

DOI:10.1007/s11606-019-05399-4
PMID:31832926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7018906/
Abstract

BACKGROUND

Colorectal cancer (CRC) screening is an evidence-based strategy to reduce CRC-related mortality.

OBJECTIVE

This study identifies physician and participant characteristics, as well as previous FIT values associated with premature FIT usage.

DESIGN

This is a retrospective review of all FITs ordered from January 1, 2016, until June 30, 2017. For each ordered FIT, the participant's chart was reviewed to identify if a previous FIT had occurred in the prior 21 months. A premature FIT was defined as an ordered test with a negative FIT in the preceding 21 months.

PARTICIPANTS

Screening participants were average risk for CRC, aged 50-74, and had a FIT ordered by their primary care provider in British Columbia, Canada.

MAIN MEASURES

The BC College of Physicians and Surgeons' database was used to identify the location of referring physician, date of graduation from medical school, and gender. The participant's age, gender, and value of previous FIT were recorded. Physician and participant variables and previous FIT value were examined with logistic regression to identify associations with premature FIT ordering.

KEY RESULTS

In total, 385,375 FITs were ordered during this period with 116,727 representing participants returning following a previous negative FIT. In total, 35,148 (30.1%) returned early for screening. Men were more likely to return early than women (OR 1.14; 95% CI 1.11-1.17; p < 0.0001). Male physicians were more likely to order premature FITs (OR 1.15; 95% CI 1.06-1.24; p < 0.0001). A higher quantitative FIT value (ng/mL) of the previous FIT was also associated with early screening (OR 1.11; 95% CI 1.09-1.14; < 0.0001).

CONCLUSIONS

This study found that approximately 30% of FIT tests, ordered for CRC screening, were ordered before they were due. This may lead to wasted resources, unnecessary participant stress, and unwarranted patient risk.

摘要

背景

结直肠癌(CRC)筛查是一种基于证据的策略,可以降低 CRC 相关死亡率。

目的

本研究确定了与 FIT 提前使用相关的医生和参与者特征以及之前的 FIT 值。

设计

这是对 2016 年 1 月 1 日至 2017 年 6 月 30 日期间所有 FIT 订单的回顾性分析。对于每个订购的 FIT,都会查阅参与者的图表,以确定在此前 21 个月内是否进行过先前的 FIT。提前进行 FIT 检测被定义为在前 21 个月内 FIT 检测结果为阴性但随后又进行 FIT 检测。

参与者

筛查参与者为 CRC 平均风险人群,年龄在 50-74 岁之间,由加拿大不列颠哥伦比亚省的初级保健医生开 FIT 检测。

主要措施

使用不列颠哥伦比亚省医师和外科医生协会的数据库确定转诊医生的位置、医学院毕业日期和性别。记录参与者的年龄、性别和之前 FIT 的值。使用逻辑回归检查医生和参与者变量以及之前的 FIT 值,以确定与 FIT 提前检测相关的因素。

主要结果

在此期间共进行了 385375 次 FIT 检测,其中 116727 次代表的是在前一次阴性 FIT 检测后返回的参与者。共有 35148 人(30.1%)提前进行了筛查。男性比女性更有可能提前返回(OR 1.14;95%CI 1.11-1.17;p<0.0001)。男性医生更有可能提前开 FIT 检测(OR 1.15;95%CI 1.06-1.24;p<0.0001)。之前 FIT 的定量值(ng/mL)越高,也与早期筛查相关(OR 1.11;95%CI 1.09-1.14;<0.0001)。

结论

本研究发现,大约 30%的 CRC 筛查 FIT 检测在规定时间之前就已经进行。这可能导致资源浪费、不必要的参与者压力和不必要的患者风险。